Metastatic Routes and Mechanisms in Malignant Tumors

Introduction to Metastasis

Malignant tumors choose different routes for metastasis based on a complex interplay of tumor-specific molecular characteristics, interactions with the microenvironment, and both mechanical and biological factors that determine their preferred metastatic sites 1, 2

Malignant tumors can spread through three main pathways: lymphatic, hematogenous (blood vessels), and direct dissemination into body cavities such as the peritoneum 3
The "seed and soil" hypothesis suggests that tumor cells (seeds) preferentially grow in specific organs (soil) that provide a favorable microenvironment for their survival and proliferation 3
The anatomical/mechanical hypothesis proposes that tumor cells spread according to vascular drainage patterns, with the first site of metastasis determined by blood flow patterns from the primary tumor 3, 4

Epithelial-mesenchymal transition (EMT) is a critical process that transforms epithelial cells into a mesenchymal phenotype with increased migratory and invasive capabilities, enabling them to metastasize through different routes 1, 5
Downregulation of intercellular adhesion molecules, particularly E-cadherin, facilitates tumor cell detachment from the primary site and promotes metastasis 1, 5
Genomic drivers like mutations in TP53, CDH1, and other genes influence the metastatic potential and preferred routes of spread 1, 6
Tumor heterogeneity within the primary tumor leads to subclones with different metastatic capabilities and preferences for specific organs 7

Gastric cancer demonstrates heterogeneous metastatic behavior, with some tumors following the anatomical/mechanical route (liver first, then lung) while others follow the seed-and-soil route with distant metastases in the absence of liver involvement 3
Renal cell carcinoma shows distinct patterns of metastasis influenced by genomic alterations in genes like SETD2, PBRM1, and MTOR, which create tumor subclones with different metastatic potentials 7
Lobular breast cancer has a unique propensity to metastasize to the peritoneum, similar to gastric cancer, likely due to specific molecular characteristics 5

The tumor microenvironment plays a crucial role in determining metastatic routes through interactions between tumor cells and stromal components 8, 6
Paracrine factors including cytokines (IL-6, IL-8), chemokines (CXCL1/CXCR1, CCL2/CCR4), and growth factors (VEGF, EGF) create favorable conditions for specific metastatic routes 8, 6
Transforming growth factor-β (TGF-β) pathway activation promotes peritoneal metastasis through increased collagen and fibronectin deposition, facilitating tumor cell adhesion 8, 6
Cancer-associated fibroblasts (CAFs) and other stromal cells influence the metastatic process through crosstalk mediated by cytokines and growth factors 8

Brain metastasis requires specialized mechanisms for tumor cells to cross the blood-brain barrier, including upregulation of genes related to mitogenesis and extracellular matrix destruction 2
Specific genes like COX2, EGFR ligand HBEGF, and ST6GALNAC5 facilitate breast cancer brain metastases, while LEF1, Cadherin 2, and KIFC1 are associated with lung cancer brain metastases 2
Complex interactions between tumor cells and brain cells, including formation of tumor-astrocyte gap junctions, promote tumor cell survival and proliferation in the brain microenvironment 2

Tumors undergo evolutionary processes with "trunk" mutations present in all tumor cells and "branched" mutations in specific subclones, creating distinct metastatic potentials 7
Parallel evolution occurs when different subclones independently develop alterations affecting the same gene or signaling pathway, enhancing metastatic capabilities 7
Convergent evolution leads to similar genomic and phenotypic profiles through different mutational pathways, creating multiple routes to metastasis 7

Understanding the molecular basis of metastatic routes can guide surveillance strategies for detecting metastasis early 1
Different metastatic patterns may require different therapeutic approaches, such as targeting specific molecular pathways involved in organ-specific metastasis 9
The American Society of Clinical Oncology notes that the heterogeneity of metastatic routes contributes to variable responses to systemic therapies between primary tumors and their metastases 2, 7

Single-cell analysis and multi-region genetic profiling are revealing the complex evolutionary trajectories that lead to different metastatic routes 7
Targeting the interaction between tumor cells and specific microenvironments may provide new therapeutic opportunities to prevent or treat metastasis 8, 2
Phenotypic profiling and pathway-based approaches are being developed to better understand and target the mechanisms driving different metastatic routes 9